Q/C Technologies, Inc. (NASDAQ: QCLS)

TNF Pharmaceuticals, Inc., also known as TNFA, is a clinical-stage pharmaceutical company operating within the biotechnology and biopharmaceutical industry. The company's primary business activities revolve around the development of two platform drugs, MYMD-1 and Supera-CBD, which target various disease indications. TNF Pharmaceuticals' operations span across numerous regions, with its headquarters located in the United States.

The company generates revenue through the development and commercialization of therapeutic platforms based on well-defined therapeutic targets. Its primary products include MYMD-1, a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, and Supera-CBD, a synthetic analog of CBD derived from the Cannabis sativa plant. These products are designed to treat a range of conditions, including rheumatoid arthritis, inflammatory bowel disease, pain, anxiety, sleep disorders, frailty, and sarcopenia. MYMD-1 has demonstrated promising results in preclinical studies, showing the potential to treat autoimmune diseases and ameliorate the course of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Supera-CBD, on the other hand, has shown therapeutic potential through in vitro binding assays and MAO inhibition studies.

TNF Pharmaceuticals holds a competitive advantage within the industry due to its focus on developing novel therapeutic platforms based on well-defined therapeutic targets. The company is currently collaborating with Bascom Palmer Eye Institute to develop MYMD-1 as a potential treatment for traumatic optic neuropathy (TON). Its key competitors include major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.

The company's customers include researchers and clinicians in the fields of autoimmune disease and inflammation, as well as pharmaceutical companies and biotechnology companies interested in developing novel therapeutic platforms. TNF Pharmaceuticals' sales and marketing infrastructure is still being developed, and the company plans to build such capabilities in North America prior to launching MYMD-1, if successfully developed and granted the requisite FDA approval. Outside of North America, the company may rely on licensing, co-sale, and co-promotion agreements with strategic partners for commercialization of its products.

In terms of its product portfolio, TNF Pharmaceuticals has 16 issued U.S. patents, three pending U.S. patent applications, 64 issued foreign patents, and 10 foreign patent applications pending in various jurisdictions. The company's intellectual property portfolio includes protection for MYMD-1 and Supera-CBD, and it relies on trademarks, know-how, confidentiality agreements, and invention assignment agreements to develop and maintain its proprietary position.

Government regulation plays a significant role in the pharmaceutical industry, and TNF Pharmaceuticals is subject to regulation by the FDA in the United States. The company must comply with various federal and state statutes and regulations governing the research, development, testing, manufacture, storage, record-keeping, approval, labeling, promotion, and marketing of its products. Failure to comply with applicable requirements may subject the company to enforcement actions and/or administrative or judicial sanctions.

The FDA approval process is a lengthy and complex process that involves several stages, including pre-clinical testing, clinical trials, and submission of a New Drug Application (NDA). The company must obtain FDA approval before marketing its products in the United States. The FDA reviews each submitted NDA before determining whether to file it and may request additional information. The FDA has committed to reviewing resubmissions in two to six months depending on the type of information included.

The company is also subject to expedited development and review programs, including fast track designation, breakthrough therapy designation, and priority review designation. These programs are designed to expedite the development and review of products that demonstrate significant improvements over existing therapies or that treat serious or life-threatening diseases.